EDMONTON, ALBERTA -- (MARKET WIRE) -- March 23, 2007 -- ViRexx Medical Corp. (TSX: VIR)(AMEX: REX), a company focused on the development of immunotherapies for certain cancers, chronic hepatitis B & C and embolotherapy for tumors, announced its financial and operational results for the fiscal year ended December 31, 2006.
